US Survey Data
New myeloproliferative neoplasm (MPN) survey data
October 10, 2016

First study in the myeloproliferative neoplasm (MPN) setting to evaluate discordance in communication and perceptions between US patients and physicians. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Mesa RA, et al. Cancer. 2016 Sep 30. […]

Inlyta Combinations for RCC
October 9, 2016

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC) October 9 2016 Based on Phase 1 results, two independent global Phase 3 trials evaluating these combinations – INLYTA plus pembrolizumab and INLYTA plus avelumab – each compared with SUTENT® (sunitinib) in first-line advanced RCC are now enrolling patients. […]

Oncology Commentaries from ESMO 2016
October 9, 2016

Science Daily Commentaries from ESMO 2016 in Copenhagen First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC European Society for Medical Oncology (ESMO) The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report. “Pembrolizumab enables T cells to […]

We are entering a truly historic era in hepatitis C therapy. The recent introduction of oral, well-tolerated, limited-duration therapies with over 95% cure rates makes the once unrealistic aspiration of eradicating hepatitis C infection a realizable goal. However, several major hurdles need to be cleared before this objective can be achieved. Foremost is the identification […]

1 35 36 37